CLINICAL AND LABORATORIAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ERYTHROID HYPERPLASIA
(Abstract release date: 05/19/16)
EHA Library. Sun A. 06/09/16; 132778; E1229
Mr. Aining Sun
Contributions
Contributions
Abstract
Abstract: E1229
Type: Eposter Presentation
Background
Myelodysplastic syndrome (MDS) is a clonal disease of hematopoietic stem cells，which is a clinically and biologically heterogeneous group of disorders associated with ineffective hematopoiesis, abnormal differentiation, and cytopenias. Approximately one third of MDS patients progress to secondary acute myeloid leukemia (sAML). Erythroid hyperplasia is very common in MDS patients，the proportion of erythroid was frequently more than thirty percent,even fifty percent, compared to ten percent to forty percent in normal bone marrow. The Erythroid hyperplasia is characterized with relatively or absolutely increase in the number of erythroid precursor cells, erythroid maturity curve shifts to the left, increase in early/late erythrocyte ratio，propagation of erythroid blasts and erythroid precursor cells. Erythroid hyperplasia is an important characteristic of MDS, however, there is still a lack of a related study of erythroid hyperplasia’s significance in MDS.
Aims
To investigate the clinical and laboratorial characteristics of patients with myelodysplastic Syndrome (MDS) and erythroid hyperplasia.
Methods
We defined MDS patients whose bone marrow was hypercellular, the proportion of erythroid was more than fifty percent, and the ratio of mature erythrocytes and nucleated erythrocytes was no more than 20 as MDS patients with erythroid hyperplasia.(MDS-E). The retrospective analysis comprised 102 patients with MDS-E from the first affiliated hospital of Suzhou university. We analyzed their clinical characteristics, karyotype, and the effect of erythroid hyperplasia on their prognosis.
Results
48 of 102(47％)MDS-E patients had a variety of cytogenetic abnormalities. The most frequent involved chromosomes were chromosomes 8(39.5% of all abnormal karyotypes), chromosomes 7(23%), followed by chromosomes 1(16.7%) and 20(16.7%). Survival analysis showed that the level of hemoglobin make a influence on prognosis. The overall survival(OS) of MDS-E patients with the level of hemoglobin more than 70 g/L was longer than that of patients whose hemoglobin concentration was less than 70 g/L(P<0.001). Hematopoietic stem cell transplantation (HSCT) could improve OS of MDS-E patients(P<0.001). In the chemotherapy group, MDS-E patients receiving chemotherapy including Decitabine had superior OS over those who were not treated with Decitabine.(P=0.014).
Conclusion
MDS-E patients have their own unique biological features compared with other MDS patients. The level of hemoglobin concentration and erythroid hyperplasia in bone marrow can affect MDS-E patients’ prognosis. The using of Decitabine in chemotherapy and HSCT can improve OS of MDS-E patients.
Session topic: E-poster
Keyword(s): Erythroid, Myelodysplasia
Type: Eposter Presentation
Background
Myelodysplastic syndrome (MDS) is a clonal disease of hematopoietic stem cells，which is a clinically and biologically heterogeneous group of disorders associated with ineffective hematopoiesis, abnormal differentiation, and cytopenias. Approximately one third of MDS patients progress to secondary acute myeloid leukemia (sAML). Erythroid hyperplasia is very common in MDS patients，the proportion of erythroid was frequently more than thirty percent,even fifty percent, compared to ten percent to forty percent in normal bone marrow. The Erythroid hyperplasia is characterized with relatively or absolutely increase in the number of erythroid precursor cells, erythroid maturity curve shifts to the left, increase in early/late erythrocyte ratio，propagation of erythroid blasts and erythroid precursor cells. Erythroid hyperplasia is an important characteristic of MDS, however, there is still a lack of a related study of erythroid hyperplasia’s significance in MDS.
Aims
To investigate the clinical and laboratorial characteristics of patients with myelodysplastic Syndrome (MDS) and erythroid hyperplasia.
Methods
We defined MDS patients whose bone marrow was hypercellular, the proportion of erythroid was more than fifty percent, and the ratio of mature erythrocytes and nucleated erythrocytes was no more than 20 as MDS patients with erythroid hyperplasia.(MDS-E). The retrospective analysis comprised 102 patients with MDS-E from the first affiliated hospital of Suzhou university. We analyzed their clinical characteristics, karyotype, and the effect of erythroid hyperplasia on their prognosis.
Results
48 of 102(47％)MDS-E patients had a variety of cytogenetic abnormalities. The most frequent involved chromosomes were chromosomes 8(39.5% of all abnormal karyotypes), chromosomes 7(23%), followed by chromosomes 1(16.7%) and 20(16.7%). Survival analysis showed that the level of hemoglobin make a influence on prognosis. The overall survival(OS) of MDS-E patients with the level of hemoglobin more than 70 g/L was longer than that of patients whose hemoglobin concentration was less than 70 g/L(P<0.001). Hematopoietic stem cell transplantation (HSCT) could improve OS of MDS-E patients(P<0.001). In the chemotherapy group, MDS-E patients receiving chemotherapy including Decitabine had superior OS over those who were not treated with Decitabine.(P=0.014).
Conclusion
MDS-E patients have their own unique biological features compared with other MDS patients. The level of hemoglobin concentration and erythroid hyperplasia in bone marrow can affect MDS-E patients’ prognosis. The using of Decitabine in chemotherapy and HSCT can improve OS of MDS-E patients.
Session topic: E-poster
Keyword(s): Erythroid, Myelodysplasia
Abstract: E1229
Type: Eposter Presentation
Background
Myelodysplastic syndrome (MDS) is a clonal disease of hematopoietic stem cells，which is a clinically and biologically heterogeneous group of disorders associated with ineffective hematopoiesis, abnormal differentiation, and cytopenias. Approximately one third of MDS patients progress to secondary acute myeloid leukemia (sAML). Erythroid hyperplasia is very common in MDS patients，the proportion of erythroid was frequently more than thirty percent,even fifty percent, compared to ten percent to forty percent in normal bone marrow. The Erythroid hyperplasia is characterized with relatively or absolutely increase in the number of erythroid precursor cells, erythroid maturity curve shifts to the left, increase in early/late erythrocyte ratio，propagation of erythroid blasts and erythroid precursor cells. Erythroid hyperplasia is an important characteristic of MDS, however, there is still a lack of a related study of erythroid hyperplasia’s significance in MDS.
Aims
To investigate the clinical and laboratorial characteristics of patients with myelodysplastic Syndrome (MDS) and erythroid hyperplasia.
Methods
We defined MDS patients whose bone marrow was hypercellular, the proportion of erythroid was more than fifty percent, and the ratio of mature erythrocytes and nucleated erythrocytes was no more than 20 as MDS patients with erythroid hyperplasia.(MDS-E). The retrospective analysis comprised 102 patients with MDS-E from the first affiliated hospital of Suzhou university. We analyzed their clinical characteristics, karyotype, and the effect of erythroid hyperplasia on their prognosis.
Results
48 of 102(47％)MDS-E patients had a variety of cytogenetic abnormalities. The most frequent involved chromosomes were chromosomes 8(39.5% of all abnormal karyotypes), chromosomes 7(23%), followed by chromosomes 1(16.7%) and 20(16.7%). Survival analysis showed that the level of hemoglobin make a influence on prognosis. The overall survival(OS) of MDS-E patients with the level of hemoglobin more than 70 g/L was longer than that of patients whose hemoglobin concentration was less than 70 g/L(P<0.001). Hematopoietic stem cell transplantation (HSCT) could improve OS of MDS-E patients(P<0.001). In the chemotherapy group, MDS-E patients receiving chemotherapy including Decitabine had superior OS over those who were not treated with Decitabine.(P=0.014).
Conclusion
MDS-E patients have their own unique biological features compared with other MDS patients. The level of hemoglobin concentration and erythroid hyperplasia in bone marrow can affect MDS-E patients’ prognosis. The using of Decitabine in chemotherapy and HSCT can improve OS of MDS-E patients.
Session topic: E-poster
Keyword(s): Erythroid, Myelodysplasia
Type: Eposter Presentation
Background
Myelodysplastic syndrome (MDS) is a clonal disease of hematopoietic stem cells，which is a clinically and biologically heterogeneous group of disorders associated with ineffective hematopoiesis, abnormal differentiation, and cytopenias. Approximately one third of MDS patients progress to secondary acute myeloid leukemia (sAML). Erythroid hyperplasia is very common in MDS patients，the proportion of erythroid was frequently more than thirty percent,even fifty percent, compared to ten percent to forty percent in normal bone marrow. The Erythroid hyperplasia is characterized with relatively or absolutely increase in the number of erythroid precursor cells, erythroid maturity curve shifts to the left, increase in early/late erythrocyte ratio，propagation of erythroid blasts and erythroid precursor cells. Erythroid hyperplasia is an important characteristic of MDS, however, there is still a lack of a related study of erythroid hyperplasia’s significance in MDS.
Aims
To investigate the clinical and laboratorial characteristics of patients with myelodysplastic Syndrome (MDS) and erythroid hyperplasia.
Methods
We defined MDS patients whose bone marrow was hypercellular, the proportion of erythroid was more than fifty percent, and the ratio of mature erythrocytes and nucleated erythrocytes was no more than 20 as MDS patients with erythroid hyperplasia.(MDS-E). The retrospective analysis comprised 102 patients with MDS-E from the first affiliated hospital of Suzhou university. We analyzed their clinical characteristics, karyotype, and the effect of erythroid hyperplasia on their prognosis.
Results
48 of 102(47％)MDS-E patients had a variety of cytogenetic abnormalities. The most frequent involved chromosomes were chromosomes 8(39.5% of all abnormal karyotypes), chromosomes 7(23%), followed by chromosomes 1(16.7%) and 20(16.7%). Survival analysis showed that the level of hemoglobin make a influence on prognosis. The overall survival(OS) of MDS-E patients with the level of hemoglobin more than 70 g/L was longer than that of patients whose hemoglobin concentration was less than 70 g/L(P<0.001). Hematopoietic stem cell transplantation (HSCT) could improve OS of MDS-E patients(P<0.001). In the chemotherapy group, MDS-E patients receiving chemotherapy including Decitabine had superior OS over those who were not treated with Decitabine.(P=0.014).
Conclusion
MDS-E patients have their own unique biological features compared with other MDS patients. The level of hemoglobin concentration and erythroid hyperplasia in bone marrow can affect MDS-E patients’ prognosis. The using of Decitabine in chemotherapy and HSCT can improve OS of MDS-E patients.
Session topic: E-poster
Keyword(s): Erythroid, Myelodysplasia
{{ help_message }}
{{filter}}